Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 86.73M P/E - EPS this Y 62.80% Ern Qtrly Grth -
Income -106.81M Forward P/E -8.35 EPS next Y -19.00% 50D Avg Chg 9.00%
Sales 14.02M PEG - EPS past 5Y - 200D Avg Chg 39.00%
Dividend N/A Price/Book 6.24 EPS next 5Y - 52W High Chg -23.00%
Recommedations 1.20 Quick Ratio 6.53 Shares Outstanding 59.69M 52W Low Chg 223.00%
Insider Own 18.03% ROA -20.81% Shares Float 44.10M Beta 1.66
Inst Own 39.80% ROE -156.45% Shares Shorted/Prior 3.75M/3.01M Price 7.10
Gross Margin -63.54% Profit Margin - Avg. Volume 259,943 Target Price 35.33
Oper. Margin -362.02% Earnings Date May 3 Volume 70,175 Change -2.07%
About Immunome, Inc.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome, Inc. News
04/26/24 Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
04/25/24 Immunome Appoints Sandra M. Swain to Board of Directors
04/05/24 Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
04/04/24 New Strong Sell Stocks for April 4th
03/28/24 Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
03/26/24 Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
03/26/24 Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
03/22/24 Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions
03/07/24 Immunome to Participate in the Leerink Partners Global Biopharma Conference
03/01/24 Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
02/20/24 Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
02/20/24 Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
02/16/24 Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
02/13/24 Immunome Announces Pricing of Public Offering of Common Stock
02/13/24 Immunome Announces Proposed Public Offering of Common Stock
02/10/24 Insiders See US$1.25m Investment In Immunome Jump Last Week
02/07/24 Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
02/06/24 Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
02/05/24 Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/08/24 Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
IMNM Chatroom

User Image Elliotwavedave Posted - 6 hours ago

$IMNM the bots are gone and the institutions are watching. Looks like they cleared away most of the bottom feeders with this sell off

User Image vikingforthewin Posted - 8 hours ago

$IMNM 🛫

User Image Elliotwavedave Posted - 8 hours ago

$IMNM when you know you should have held

User Image DonCorleone77 Posted - 9 hours ago

$IMNM Immunome initiated with an Overweight at JPMorgan JPMorgan initiated coverage of Immunome with an Overweight rating and $24 price target. The company is "turning a new page" following a transformational year after a merger and multiple deals, the analyst tells investors in a research note. The firm says Immunome's pipeline now combines a pivotal stage asset and multiple early-stage programs in areas that are of significant investor interest. It finds the story "intriguing," saying AL102 in desmoid tumors is the major driver in valuation today, and the rest of the pipeline is largely overlooked by investors.

User Image MGAP Posted - 2 days ago

$IMNM Thinking about entry mid day- to end of day. Looking primed here. let us see

User Image ViractaTrader77 Posted - 3 days ago

Game Changer https://markets.businessinsider.com/news/stocks/sutro-biopharma-s-lead-ovarian-cancer-candidate-is-a-game-changer-analyst-sees-huge-upside-1032685474 $IBRX $IOVA $BOLT $IMNM

User Image Durand32 Posted - 4 days ago

$IMNM It's back to where it was when I sold. I missed out on the inexplicable run to $30. I guess I have another chance now, but I still don't see any catalysts coming until next year

User Image Jeff9905 Posted - 4 days ago

$IMNM 62m loss and counting. Not good.

User Image HunterT Posted - 4 days ago

$IMNM hoping it levels off here, little bird told me that the selling should be almost finished 🤞🏻 hopefully a recovery into the 20s and $40 by December 🙏🏻 shares that were locked up became available to the past regime employed and they all wanted out in the last two weeks. Millions of shares sold into the open market! Hopefully it was just a speed bump

User Image Elliotwavedave Posted - 4 days ago

$IMNM Sandra swain from Seagen now on board with board of directors.

User Image Jeff9905 Posted - 5 days ago

$IMNM yep. Gotta step on that 60m loss. Pathetic.

User Image Elliotwavedave Posted - 5 days ago

$IMNM time for the orchestrated algo selloff that starts around 3pm

User Image ViractaTrader77 Posted - 5 days ago

$IMNM best adc stock available

User Image intratio Posted - 5 days ago

$IMNM The automated equity analyst deduces that the stock price of this company is not likely to rise soon and projects a dramatically gloomy future

User Image Jeff9905 Posted - 6 days ago

$IMNM 60m loss to the poor folks that got suckered into the secondary. Sad.

User Image Mansuur Posted - 6 days ago

$IMNM

User Image Elliotwavedave Posted - 6 days ago

$IMNM those 3 pm short algo selloffs we’ve had lately are interesting.

User Image Jeff9905 Posted - 1 week ago

$IMNM looks like selling far from over. Going back to Sharma days. Will reload at 5.

User Image Mansuur Posted - 1 week ago

$IMNM like trash

User Image HunterT Posted - 1 week ago

$IMNM selling should be about done… should return to highs this year from what I’m hearing.

User Image Jeff9905 Posted - 1 week ago

$IMNM more sellling on high volume. Nothing is working.

User Image intratio Posted - 1 week ago

https://www.intratio.com/stock-forecast/IMNM The AI has predicted the stock price of this company will depreciate in the short-term and, in the long run, faces severe disadvantages $IMNM

User Image Jeff9905 Posted - 1 week ago

$IMNM another huge sell at close. Not good.

User Image Jjpratt19 Posted - 1 week ago

$IMNM you all need to look at the market before thinking "something is wrong". Something is wrong with everything right now. Isreal retaliated against Iran, we just offered up another 95bn in aide, fear of a possible rate HIKE in June.... The entire market is down, and bio is getting thrashed even more so. How do startup bios thrive? With cash...expensive cash borrowing hurts even more. My portfolio is down about 35% from our highs end of Feb/early March.

User Image Fast_Eddie_Felson Posted - 1 week ago

$IMNM looking like garbage again…and all those tutes got screwed buying at 21-22

User Image Jeff9905 Posted - 1 week ago

$IMNM dropping on high volume this time. Something isn't right.

User Image Jeff9905 Posted - 1 week ago

$IMNM i hope the underwriters that sold this to clients at 20 are demanding something! Rate cuts are a non issue. Clay factor probably overrated.

User Image HunterT Posted - 1 week ago

$IMNM where’s the bottom 🧐

User Image Jeff9905 Posted - 1 week ago

$IMNM 2 more job postings yesterday

User Image HunterT Posted - 2 weeks ago

$IMNM oof cmon

Analyst Ratings
Guggenheim Buy Apr 15, 24
Wedbush Outperform Apr 1, 24
Wedbush Outperform Jan 23, 24
Wedbush Outperform Dec 19, 23
Cantor Fitzgerald Overweight Mar 20, 23
Chardan Capital Buy Mar 17, 23
Cantor Fitzgerald Overweight Oct 29, 21
Chardan Capital Buy Oct 27, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SIEGALL CLAY B President and CEO President and CEO Oct 02 Buy 5.91 169,204 999,996 319,636 10/04/23
Turner Bruce Chief Strategy Offic.. Chief Strategy Officer Oct 02 Buy 5.91 42,300 249,993 42,300 10/04/23
RAPP MICHAEL Director Director Sep 13 Buy 17.92 45,950 823,424 182,780 09/13/21